Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: Results of an open-label, phase 3b study

Advances in Therapy

Volumn 30, Issue 3, 2013, Pages 229-259

  Gálvez, Rafael ^a   Schäfer, Michael ^b   Hans, Guy ^c   Falke, Dietmar ^d   Steigerwald, Ilona ^d  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d GRÜNENTHAL GMBH   (Germany)

Author keywords

Chronic pain; Equianalgesic; Equipotency; Low back pain; Neuropathic pain; Opioid; Severe pain; Tapentadol

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROMORPHONE; MORPHINE; OPIATE; OXYCODONE; TAPENTADOL; DELAYED RELEASE FORMULATION; NARCOTIC ANALGESIC AGENT; PHENOL DERIVATIVE;

ADULT; ANALGESIA; ARTICLE; COMPARATIVE STUDY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEALTH STATUS; HEALTH SURVEY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; MEDICAL HISTORY; NEUROPATHIC PAIN; PAIN ASSESSMENT; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; SHORT FORM 36; WITHDRAWAL SYNDROME; WORLD HEALTH ORGANIZATION; AGED; CHEMICALLY INDUCED; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DELAYED RELEASE FORMULATION; MIDDLE AGED; MULTICENTER STUDY; NEURALGIA; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; THERAPEUTIC USE; CHEMICALLY INDUCED DISORDER;

ADULT; AGED; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC PAIN; CONSTIPATION; DELAYED-ACTION PREPARATIONS; FEMALE; FENTANYL; HUMANS; HYDROMORPHONE; LOW BACK PAIN; MALE; MIDDLE AGED; MORPHINE; NEURALGIA; OXYCODONE; PAIN MEASUREMENT; PHENOLS; SEVERITY OF ILLNESS INDEX;

EID: 84891336693     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0015-6     Document Type: Article

References (39)

1. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147:478-91.
2. Chou R, Huffman LH. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med. 2007;147:505-14.
3. Christo PJ. Opioid effectiveness and side effects in chronic pain. Anesthesiol Clin North America. 2003;21:699-713.
4. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7:R1046-51.
5. Ballantyne JC. Opioids for chronic nonterminal pain. South Med J. 2006;99:1245-55.
6. Gregorian RS, Jr., Gasik A, Kwong WJ, Voeller S, Kavanagh S. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain. 2010;11:1095-108.
7. Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, andmanagement options. Pain Med. 2009;10:654-62.
8. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35-42.
9. Duensing L, Eksterowicz N, Macario A, Brown M, Stern L, Ogbonnaya A. Patient and physician perceptions of treatment of moderate-to-severe chronic pain with oral opioids. Curr Med Res Opin. 2010;26:1579-85.
10. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-1e88.
11. Bartleson JD. Evidence for and against the use of opioid analgesics for chronic nonmalignant low back pain: a review. Pain Med. 2002;3:260-71.
12. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin. 2009;25:2133-50.
13. Varrassi G, Muller-Schwefe GH. The international CHANGE PAIN physician survey: does specialism influence the perception of pain and its treatment? Curr Med Res Opin. 2012;28:823-31.
14. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012;7:CD008943.
15. Tzschentke TM, Christoph T, Kögel B, et al. (-)-(1R,2R)-3-(3- Dimethylamino-1-ethyl-2-methylpropyl)- phenol hydrochloride (tapentadol HCl): a novel m-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323:265-76.
16. Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol hydrochloride. Analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitor. Drugs Future. 2006;31:1053-61.
17. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Invest. 2010;30:489-505.
18. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placeboandactive-controlled phase III study. Expert Opin Pharmacother. 2010;11:1787-804.
19. Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010;27:381-99.
20. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results ofa randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27:151-62.
21. Wild JE, Grond S, Kuperwasser B, et al. Longterm safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10:416-27.
22. Steigerwald I, Müller M, Davies A, et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin. 2012;28:911-36.
23. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9-19.
24. Farrar JT, Young JP, Jr., LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-58.
25. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11:S22-S32.
26. Selai CE, Trimble MR, Price MJ, Remak E. Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs. Curr Med Res Opin. 2005;21:733-9.
27. Ware JE, Jr., Donald Sherbourne C. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-83.
28. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52:69-77.
29. Snaith RP. The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes. 2003;1:29.
30. Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911-20.
31. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248-57.
32. Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep. 2009;13:185-90.
33. Tolle TR, Gockel U, Baron R, et al. Test and re-test of the painDETECT questionnaire (PD-Q). Abstract accepted for presentation at: the 4th International Congress on Neuropathic Pain (NeuPSIG 2013); 23-26 May, 2013; Toronto, Canada.
34. Tarulli AW, Raynor EM. Lumbosacral radiculopathy. Neurol Clin. 2007;25:387-405.
35. Biondi DM, Xiang J, Benson C, Etropolski M, Moskovitz B, Rauschkolb C. Tapentadol IR versus oxycodone IR for treatment of acute low back pain. Pain Physician. 2012. In press.
36. Schröder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther. 2011;337:312-20.
37. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32:304-15.
38. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004;CD004847.
39. Thomsen AB, Becker N, Eriksen J. Opioid rotation in chronic non-malignant pain patients. A retrospective study. Acta Anaesthesiol Scand. 1999;43:918-23.